Analyst Ratings For AnaptysBio Inc (NASDAQ:ANAB)
Today, Guggenheim initiated coverage on AnaptysBio Inc (NASDAQ:ANAB) with a Buy.
There are 10 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on AnaptysBio Inc (NASDAQ:ANAB) is Buy with a consensus target price of $127.20 per share, a potential 95.87% upside.
Some recent analyst ratings include
- 2/22/2019-AnaptysBio Inc (NASDAQ:ANAB) has coverage initiated with a Buy rating
- 12/20/2018-AnaptysBio Inc (NASDAQ:ANAB) has coverage initiated with a Buy ➝ Buy rating and $126.00 price target
- 11/21/2018-AnaptysBio Inc (NASDAQ:ANAB) has coverage initiated with a Overweight ➝ Overweight rating and $115.00 price target
- On 1/15/2019 Marco Londei, Insider, sold 19,075 with an average share price of $69.88 per share and the total transaction amounting to $1,332,961.00.
- On 1/14/2019 Hamza Suria, CEO, sold 40,000 with an average share price of $70.79 per share and the total transaction amounting to $2,831,600.00.
- On 12/17/2018 Marco Londei, Insider, sold 30,048 with an average share price of $66.76 per share and the total transaction amounting to $2,006,004.48.
- On 12/14/2018 Hamza Suria, CEO, sold 41,728 with an average share price of $69.36 per share and the total transaction amounting to $2,894,254.08.
- On 12/12/2018 Hamza Suria, CEO, sold 65,585 with an average share price of $71.47 per share and the total transaction amounting to $4,687,359.95.
- On 12/10/2018 Hamza Suria, CEO, sold 30,587 with an average share price of $71.19 per share and the total transaction amounting to $2,177,488.53.
- On 12/3/2018 Dominic Piscitelli, CFO, sold 37,000 with an average share price of $72.14 per share and the total transaction amounting to $2,669,180.00.
About AnaptysBio Inc (NASDAQ:ANAB)
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.
Recent Trading Activity for AnaptysBio Inc (NASDAQ:ANAB)
Shares of AnaptysBio Inc closed the previous trading session at 64,94 −0,090 0,14 % with 63.99 shares trading hands.
